Today there seems to be a multitude of articles discussing either how to do things right, or just how f-ed up all the privates and small caps are. We did a scouring and found several sources who put in their 2 clams on the present and the future…

John Taylor, VP of Research at the NVCA said that:

…biotech in New England is expected to drive sector-specific growth. Looking ahead, it is all about sectors. Especially in clean tech, biotech, and medical devices, the focus is on finding the best companies, wherever they happen to be…keep an eye on sectors with increased government funding such as security and defense, biotech, cleantech, etc.

Bruce Bigelow of Xconomy, who writes great pieces btw, pumped some San Diego VCs for info. Jay Lichter of Avalon Ventures, whose strategy is to make small, early investments ($3-4M) and make an early exit by selling to a big dawg for $20-30M, told Xconomy:

“I can’t think of a time when a venture group got a significant outcome from a company through an IPO. There really is only one exit and that is through a big pharmaceutical buyout. When you see some VCs making significant investments of $60-$80-$100 million, it’s hard to see how they’re going to get their money out.”

Makes sense, good “strategery” we say.

You girls also gotta check out Top Gold News and the WSJ. TGN talks about all these biotechs who missed the IPO boat – sucks. The WSJ has some good stuff about biotechs looking for government money.

Tough times…tough times indeed.

Image from stickerbugs

Related Posts